Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Accounts Payables (2023 - 2025)

Ascentage Pharma Group International posted quarterly Accounts Payables of $15.0 million for Q4 2025, up 17.55% year-on-year from $12.8 million in Q4 2024, and down 9.16% on a QoQ basis from $16.6 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Accounts Payables data on file, last reported at $15.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 17.55% year-over-year to $15.0 million; the trailing twelve-month figure through Dec 2025 stood at $15.0 million (up 17.55% YoY), and the FY2025 full-year result was $15.3 million, up 21.15% from the prior year.
  • Accounts Payables for Q4 2025 stood at $15.0 million, down from $16.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $16.6 million in Q2 2025 and bottomed at $10.1 million in Q4 2023.
  • The 3-year median for Accounts Payables is $13.9 million (2024), against an average of $13.6 million.
  • The widest annual swing landed in 2024, when Accounts Payables advanced 27.25%; it then increased 17.55% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $10.1 million in 2023, then rose by 27.25% to $12.8 million in 2024, then increased by 17.55% to $15.0 million in 2025.
  • The last three Accounts Payables figures came in at $15.0 million (Q4 2025), $16.6 million (Q2 2025), and $12.8 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Accounts Payables (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 1.05 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 83.00 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 10.62 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 8.64 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 489.30 Mn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 1.03 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 126.63 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 15.05 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 15.05 Mn
Jun 30, 2025 16.57 Mn
Dec 31, 2024 12.80 Mn
Dec 31, 2023 10.06 Mn